UK respiratory disease focussed biotech firm Synairgen (LSE: SNG) has announced the expansion of the placebo-controlled home setting clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in patients with COVID-19.
The trial has been expanded beyond the Southampton area to include patients across the majority of the UK, and the positive development impressed investors, as Synairgen’s shares were up 2.24% at 39.87 pence as trading neared close today.
Patients in almost any part of the UK who have tested positive for coronavirus, and meet the additional eligibility criteria, can now participate in the home setting arm of Synairgen's COVID-19 trial. Daily video calls with a doctor or nurse will be conducted to supervise dosing with the study medication and for the assessment of trial endpoints. All trial supplies, including a pulse oximeter, thermometer, nebulizer and the trial drug, will be delivered directly to the patient, minimizing the chance of spreading the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze